Orforglipron
Also known as: Orforglipron
Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist in late-stage clinical development for obesity and type 2 diabetes. It is studied for weight loss and glycemic control without injections.
Last updated
Mechanism of Action
Orforglipron is a small-molecule, non-peptide agonist of the glucagon-like peptide-1 (GLP-1) receptor that, unlike peptide GLP-1 drugs, is orally bioavailable and not degraded in the gut. Activation of the GLP-1 receptor stimulates glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying. Centrally, GLP-1 receptor signaling in the hypothalamus and brainstem reduces appetite and food intake, driving weight loss. Its small-molecule structure allows once-daily oral dosing without the food and water restrictions of peptide-based oral semaglutide.
- Half-life
- Long enough to support once-daily oral dosing, roughly in the range of a day
- Administration Routes
- oral
- Research Status
- Clinical
Reported Benefits
- Oral administration without injections
- Significant weight loss in clinical trials
- Improves glycemic control in type 2 diabetes
- Glucose-dependent insulin secretion lowers hypoglycemia risk
- Reduces appetite and caloric intake
- No strict fasting requirements unlike oral peptide GLP-1 agents
Potential Side Effects
- Nausea, especially during dose escalation
- Vomiting or diarrhea
- Constipation
- Decreased appetite
- Transient dyspepsia or abdominal discomfort
Common Dosing
For research and informational reference only and not personal medical advice: clinical trials use once-daily oral dosing with gradual titration across several milligram dose levels. Dosing should follow trial protocols or clinician guidance.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Pregnancy or breastfeeding
- History of pancreatitis without clinician oversight
GLP-3 R
GLP-3 R is an investigational triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors, studied for substantial weight loss and improved glycemic control. It is one of the most potent incretin-based agents in late-stage clinical development.
Cagrilintide
Cagrilintide is a long-acting amylin analog developed for weight management, often paired with semaglutide. It slows gastric emptying and increases satiety to reduce food intake.
Tesofensine
Tesofensine is a triple monoamine reuptake inhibitor originally developed for neurodegenerative disease and later investigated as an anti-obesity drug. It produces appetite suppression and notable weight loss in clinical trials. Note: Tesofensine is a small-molecule triple monoamine reuptake inhibitor, not a peptide, but is sold alongside metabolic research compounds.
Survodutide
Survodutide (BI 456906) is an investigational dual agonist of the glucagon and GLP-1 receptors developed for obesity and metabolic dysfunction-associated steatohepatitis (MASH). It is administered as a once-weekly subcutaneous injection.
- View
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
2026
- View
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
2025
- View
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
2025
- View
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
2023